Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users

X
Trial Profile

A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocodone/paracetamol (Primary) ; Hydrocodone; Paracetamol
  • Indications Pain
  • Focus Pharmacodynamics; Registrational
  • Sponsors Acura Pharmaceuticals
  • Most Recent Events

    • 26 Aug 2013 Primary endpoint 'Drug cravings' (subject like/dislike scores) has not been met according to an Acura Pharmaceuticals media release.
    • 26 Aug 2013 Primary endpoint 'Drug-cravings' has not been met.
    • 26 Aug 2013 Acura Pharmaceuticals will further evaluate trial results with plans to meet with the US FDA for discussion. The NDA submission will likely be delayed as a consequence of failure to demonstrate statistical significance for the primary endpoint.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top